Completion of placing of new shares under general mandate
Filed with HKEX · Stock code 9926 · · 3 pages · English
Summary by 6ix AI
Akeso, Inc. has completed the placing of new shares under a general mandate, as announced on page two. The placing involved an aggregate of shares placed to independent professional and institutional investors, also detailed on page two. The shareholding structure of the company before and after the placing is provided on page two.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Akeso
- Placing of new shares under general mandate
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- 2026 Interim report
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
- Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
Later from Akeso
- Next Day Disclosure Return
- Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
Follow Akeso into a list and get an email when it puts out news.
Follow Akeso